Pabst Patent Group | Pharmaceutical
This links to the home page
Pharmaceutical

Pabst Patent Group (PPG) helps pharmaceutical companies protect the intellectual property underlying new drugs and medical treatments, commercialize their discoveries, and attract investment.

Our lawyers and advisors have advanced degrees and extensive experience in pharmacology, medicinal chemistry, organic chemistry, polymer chemistry, biochemistry, physiology, genetics, neuroscience, immunology, drug delivery, and regulatory affairs. This focus, combined with our deep knowledge of the pharmaceutical industry, gives clients a crucial edge in navigating this complex, constantly evolving legal environment.

We take the time to learn about our clients’ business goals and build proactive strategies that minimize risk and deliver superior value. We understand the business and science of drug discovery—from the high stakes involved in financing research and development to the rigorous and arcane regulatory process for new products. In close collaboration with clients, we provide the full gamut of intellectual property counsel, from strategic counseling to patent prosecution, due diligence, legal opinions, and litigation support.


Pharmaceutical IP Services


Services we have provided our pharmaceutical industry clients include:
  • IP strategy development
  • IP audit and landscape analysis
  • Prosecuting and filing patent applications in the U.S. and foreign jurisdictions
  • Representation in patent interferences, reexamination proceedings, and international oppositions
  • Litigation support
  • Due diligence for mergers, acquisitions, and partnering
  • Drafting and negotiating license agreements
  • Trademark prosecution and counseling


Notable Work


Below are exemplary patents that we have obtained for our clients in the pharmaceutical industry:
  • US Patent no. 11,116,737 “Methods of using probenecid for treatment of coronavirus infections” assigned to University of Georgia Research Foundation
  • US Patent no. 10,953,036 “Compositions and methods of modulating HIF-2A to improve muscle generation and repair” assigned to University of Georgia Research Foundation
  • US Patent no. 10,912,834 “Topical Formulations based on Ionic Species for Skin Treatment” assigned to The Regents of the University of California
  • US Patent no. 10,828,265 “Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery” assigned to The Regents of the University of California
  • US Patent no. 10,722,468 “Compositions for Stabilizing and Delivering Proteins” assigned to Brown University
  • US Patent no. 10,653,789 “Polymer-drug conjugates for combination anticancer therapy” assigned to The Regents of the University of California